Supplementary Table 1. Delivery routes and the biosafety of oncolytic virus

	Virus type	Oncolytic virus	Indication	Reference
Delivery routes				
Intratumoral administration	HSV	HSV1716	Extracranial cancers	(44)
	Adenovirus	VCN-01	Retinoblastoma	(46)
	Vesicular stomatitis virus	VSV∆51	Melanoma	(39)
	Alphavirus	M1	Glioblastoma	(40)
	HSV	HF10	Pancreatic carcinoma	(50)
	Reovirus	Reovirus	Astrocytoma	(51)
	Reovirus	Reovirus	Gliomas	(48)
	Poxvirus	CF33-hNIS	Colon cancer	(45)
	Poxvirus	CF33	Triple-negative breast cancer	(47)
	Poxvirus	CF33-Fluc	Colorectal cancer	(69)
Intravenous administration	Reovirus	Reovirus	Astrocytoma	(53)
	Vaccinia virus	OVV-CXCR4-A-Fc	Neuroblastoma	(54)
	HSV	G207	Supratentorial malignant tumors	(56)
	Poxvirus	Poxvirus	Neuroblastoma	(55)
	Adenovirus	Ad-IAI.3B	Lung squamous cell carcinoma	(57)
	Alphavirus	M1	Bladder cancer	(58)
	Reovirus	Reovirus	Carcinoma ovarii, Carcinoma of fallopian tube, Peritoneal carcinoma	(60)
	Maraba virus	MG1	Prostatic carcinoma	(59)
	Adenovirus	Ad6	Prostate cancer	(61)
	HSV	T-VEC	Melanoma	(63)
	Measles virus	MV-GFP	Atypical teratogenic rhabdoid tumor	(64)
Intraperitoneal administration	HSV	oHSV-1	Kaposi's sarcoma, angiosarcoma, epithelioid sarcoma	(65)
	Adenovirus	ONCOS-102	Gastrointestinal stromal tumor, leiomyosarcoma, liposarcoma	(67)
	Poxvirus	CF33	Pancreatic carcinoma	(66)
Intrathecal treatment	Poliovirus	PVS-RIPO	Glioblastoma, Glioma, Ependymoma, Primitive neuroectodermal tumor,	(68)

(67)
(112 114)
(113, 114)
(77)
ant (104)
(104)
(105, 106)
(105, 106)
(107, 108)
(7.4)
(74)
(75)
(91)
(82, 83, 86, 109)
(85)
(84, 101)
(92)
,
(93, 94)
(96)
(60)
(60)
(78)
all
(112)
al

			mesothelioma
Neither Common or Severe adverse events (No reports yet)	HSV	ОН2	Intestinal cancer
	Adenovirus	LOAd703	Pancreatic cancer
	Pox virus	vvDD	
	Coxsackie virus	Cavatak	Head and neck cancer, melanoma
	Newcastle disease virus	NVD	Glioblastoma, sarcoma, neuroblastoma

Note:

Common adverse events include flulike symptoms (fever, fatigue, nausea, vomiting), local injection reaction (inflammation, erythema and rash at the injection site), headache, back pain, anemia, leukopenia, neutropenia, liver dysfunction, weight loss, elevated liver enzymes, thrombocytopenia, bladder spasm, hematuria, dysuria, urgency, abdominal pain, glucose abnormalities, hair loss, mild electrolyte disturbances, hypotension, tachycardia, hypertension, anorexia, myalgia, diarrhea.

Severe adverse events include severe hypotension, tachycardia, cellulitis, dyspnea, pleural effusion, urinary tract infection, hydrocephalus, seizures, varicella zoster infection, brain edema, speech disorder, encephalitis, hepatitis, viral infection, perforated peritonitis, severe liver dysfunction, viremia, severe dysuria, dehydration, intestinal obstruction, hypokalemia, severe leukopenia, sepsis, pulmonary embolism, edema, pustules, severe lymphopenia, severe fever, severe headache, pancreatitis, severe neutropenia, severe diarrhea, arthralgia, biliary duct proliferation, decreased consciousness.

The references of the right column are listed in the main text of this publication.